Sirijatuphat 2022.
Study characteristics | |
Methods | Multicentre, open‐label RCT |
Participants | People with mild cases of COVID‐19 without pneumonia. |
Interventions | Favipiravir, standard of care |
Outcomes | Favipiravir's effects on viral clearance, clinical improvement, risk of COVID‐19 pneumonia development, adverse events |
Notes |